Centre National De La Recherche Scientifique

Universiteit Gent

Vib Vzw

Centre Hospitalier Régional Universitaire De Montpellier

Universitè De Montpellier

Universität Osnabrück

Institut National De La Sante Et De La Recherche Medicale

Centre Hospitalier Universitaire De Montpellier

Universite Montpellier 2

Universite Montepellier 2

Inserm (institut National De La Sante Et De La Recherche Medicale)

Guillaume Cartron

Jan Tavernier

Franciane Paul

Jacob Piehler

Gilles Uzé

Jérôme Moreaux

Caroline Bret

Angelos Constantinou

Philippe Pasero

This disclosure relates to a modified &#x3b1;-helical bundle cytokine, with reduced activity via an &#x3b1;-helical bundle cytokine receptor, wherein the &#x3b1;-helical bundle cytokine is specifically delivered to target cells. Preferably, the &#x3b1;-helical bundle cytokine is a mutant, more preferably it is a mutant interferon, with low affinity to the interferon receptor, wherein the mutant interferon is specifically delivered to target cells. The targeting is realized by fusion of the modified &#x3b1;-helical bundle cytokine to a targeting moiety, preferably an antibody. This disclosure relates further to the use of such targeted modified &#x3b1;-helical bundle cytokine to treat diseases. A preferred embodiment is the use of a targeted mutant interferon, to treat diseases, preferably viral diseases and tumors.

Targeted and mutated human-interferon fusion proteins

The present invention relates to a method of testing whether a patient suffering from arge B-cell lymphoma will respond or not to a DNA repair pathway inhibitor comprising: i) determining the expression level (ELi) of several genes Gi-Gn selected from table A in a biological sample obtained from said patient comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the DNA repair score trough the following formula (I), wherein &#x3b2;i represent the regression &#x3b2; coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=&#x2212;1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score DNARS determined at step iii) with a predetermined reference value DNARSv) and concluding that the patient will respond to the treatment when the DNARS score is higher than the predetermined reference value DNARSor concluding that the patient will not respond to the treatment when the DNARS score is lower than the predetermined reference value DNARS. 

Methods for predicting response to DNA repair pathway inhibitors in diffuse large B-cell lymphoma

Targeted human-interferon fusion proteins

Growing community of inventors

Combaillaux, France

Guillaume Cartron